Appendix E: Renal Services Described for Non-physicians

(Reproduced from the third edition of the Renal Association Standards document)

This annex gives information on the issues discussed above in this document, provides background information on renal failure, and discusses the services available for its treatment.

Renal Diseases

E.1.1 Diseases of the kidney are not as common as cardiovascular conditions or cancers but are much more common than some well known disorders such as multiple sclerosis or muscular dystrophy. Renal conditions account for about 7,000 deaths per annum according to the Registrar General’s figures, but these are probably an underestimate since about one third of deaths of patients with renal failure are not recorded as such in mortality statistics. These figures exclude deaths from cancers of the kidney and associated organs of the urinary tract such as bladder and prostate.

E.1.2 Over 100 different diseases affect the kidneys. These diseases may present early with features such as pain, the presence of blood or protein in the urine, or peripheral oedema (swelling of the legs), but much renal disease is self-limiting; it occurs and heals with few or no symptoms or sequelae. On the other hand, some kidney diseases start insidiously and progress but are undetected until renal failure develops.

Acute Renal Failure

E.1.3 Renal failure may be acute and reversible. It occurs in previously normal kidneys when their blood supply is compromised by a fall in blood pressure caused by crush injuries, major surgery, failure of the heart’s pumping action, loss of blood, salt or water, or when they are damaged by poisons or overwhelming infection. Renal support is then needed for a few days or weeks before renal function returns. However, about half such patients die during the illnesses because of other conditions, often the one which caused the renal failure.

Chronic Renal Failure (CRF) and Established Renal Failure (ERF)

E.1.4 More common is chronic irreversible renal failure, in which the kidneys are slowly destroyed over months or years. To begin with there is little to see or find, and this means that many patients present for medical help very late in their disease, or even in the terminal stages. Tiredness, anaemia, a feeling of being ‘run down’ are often the only symptoms. However, if high blood pressure develops, as often happens when the kidneys fail, or is the prime cause of the kidney disease, it may cause headache, breathlessness and perhaps angina. Ankle swelling may occur if there is a considerable loss of protein in the urine.

E.1.5 Progressive loss of kidney function is also called chronic renal failure. Early chronic renal failure is sometimes referred to as chronic renal impairment or insufficiency, and end stage renal disease when it reaches its terminal stage. At this point, if nothing is done, the patient will die. Two complementary forms of treatment – dialysis and renal transplantation – are available and both are needed if end stage renal disease is to be treated.

E.1.6 The incidence of chronic renal disease and end stage renal failure rises steeply with advancing age. Increasing numbers of patients treated for end stage renal disease in this country are elderly and the proportion is even higher in some other developed countries. Evidence from the United States suggests that the relative risk of end stage renal failure in the black population (predominantly of African origin) is two to four times higher than for whites. Data collected during the review of renal specialist services in London suggest that there is in the Thames regions a similar greater risk of renal failure in certain ethnic populations (Asian and Afro-Caribbean) than in whites this is supported by national mortality statistics. People from the Indian subcontinent have a higher prevalence of non-insulin dependent diabetes, and those with diabetes are more likely than whites to develop renal failure. This partly explains the higher acceptance rate of Asians on to renal replacement programmes.

Causes of Renal Failure

E.1.7 Most renal diseases that cause renal failure fall into a few categories.
Systematic disease. Although many generalised diseases such as systemic lupus, vasculitis, amyloidosis and myelomatosis can cause kidney failure, by far the most important cause is diabetes mellitus (about 20% of all renal disease in many countries). Progressive kidney damage may begin after some years of diabetes, particularly if the blood sugar and high blood pressure have been poorly controlled. Careful lifelong supervision of diabetes has a major impact in preventing kidney damage.

Autoimmune disease. ‘Glomerulonephritis’ or ‘nephritis’ describes a group of diseases in which the glomeruli (the filters that start the process of urine formation) are damaged by the body’s immunological response to tissue changes or infections elsewhere. Together, all forms of nephritis account for about 30% of renal failure in Britain. The most severe forms are therefore treated with medications that suppress response, but treatment makes only a small impact on the progress of this group of patients to end stage renal failure.

High blood pressure. Severe (‘accelerated’) hypertension damages the kidneys, but the damage can be halted – and to some extent reversed – by early detection and early treatment of high blood pressure. This is a common cause of renal failure in patients of African origin.

Obstruction. Anything that obstructs the free flow of urine can cause backpressure on the kidneys. Much the commonest cause is enlargement of the prostate in elderly men, although only a small proportion of them develop kidney failure over the age of 70.

Infection of the urine. Cystitis is a very common condition, affecting about half of all women at some time in their lives, but it rarely has serious consequences. However, infections of the urine in young children or patients with obstruction, kidney stones or other abnormalities of the urinary tract may result in scarring of the kidney and eventual kidney failure.

Genetic disease. One common disease, polycystic kidneys, and much rarer inherited disease, affecting the kidneys, account for about 8% of all kidney failure in Britain. Although present at birth, polycystic kidney disease often causes no symptoms until middle age or later. Understanding of its genetic basis is rapidly advancing and may lead to the development of effective treatment.

Although many diseases causing chronic renal failure cannot be prevented or arrested at present, better control of diabetes and high blood pressure and relief of obstruction have much to offer, provided they are employed early in the course of the disease before much renal damage has occurred. It has also been shown that a group of antihypertensives called angiotension1 converting enzyme inhibitors (ACE1) delay the progression of renal failure. Screening for renal disease has not been widely practised, because the relatively low incidence of cases renders population screening inefficient and costly. Urine tests for protein or blood, or blood tests for the level of some substances normally excreted by the kidney such as creatinine and urea, are potentially useful methods for screening, if populations at risk for renal failure can be identified, e.g. diabetics and the elderly.

Renal failure is often accompanied by other disease processes. Some are due to the primary disease, e.g. diabetes may cause blindness and diseases of the nerves and blood vessels. Others, such as anaemia, bone disease and heart failure, are consequences of the renal failure. Coincidental disease such as chronic bronchitis and arthritis are particularly common in older patients with renal failure. In addition many patients with end stage renal disease have diseases affecting the heart and blood vessels (vasculitis) particularly ischaemic heart disease and peripheral vascular disease. All these conditions, collectively called co-morbidity, can influence the choice of treatment for renal failure and may reduce its benefits. Expert assessment of the patient before end stage renal failure can reduce co-morbidity and increase the benefit and cost effectiveness of treatment. Thus early detection and referral of patients at risk of renal failure is important.
The term renal replacement therapy is used to describe treatments for end-stage renal failure in which, in the absence of kidney function, the removal of waste products from the body is achieved by dialysis and other kidney functions are supplemented by drugs. The term also covers the complete replacement of all kidney functions by transplantation.

Dialysis involves the removal of waste products from the blood by allowing these products to diffuse across a thin membrane into dialysis fluid which is then discarded along with the toxic waste products. The fluid is chemically composed to draw or ‘attract’ excess salts and water from the blood to cross the membrane, without the blood itself being in contact with the fluid.

The method first used to achieve dialysis was the artificial kidney, or haemodialysis. This involves the attachment of the patient’s circulation to a machine through which fluid is passed, and exchange can take place. A disadvantage of this method is that some form of permanent access to the circulation must be produced to be used at every treatment. Each session lasts 4–5 hours and is needed three times a week.

The alternative is peritoneal dialysis, often carried out in the form of continuous ambulatory peritoneal dialysis (CAPD). In this technique, fluid is introduced into the peritoneal cavity (which lies around the bowel) for approximately 6 hours before withdrawal. The washing fluid must be sterile in order to avoid peritonitis (infection and inflammation of the peritoneum), which is the main complication of the treatment. A silastic tube must be implanted into the peritoneum and this may give problems such as kinking and malposition. Each fluid exchange lasts 30–40 minutes and is repeated three or four times daily. Neither form of dialysis corrects the loss of the hormones secreted by the normal kidney so replacement with synthetic erythropoietin and vitamin D is often necessary.

Renal transplantation replaces all the kidneys functions, so erythropoietin and vitamin D supplementation are unnecessary. A single kidney is placed, usually in the pelvis close to the bladder to which the ureter is connected. The kidney is attached to a nearby artery and vein. The immediate problem is the body’s acute rejection of the foreign graft, which has largely been overcome during the first months using drugs such as steroids and cyclosporin. These drugs, and others that can be used for that purpose, have many undesirable side effects, including the acceleration of vascular disease, so myocardial infarcts and strokes are commoner in transplant patient than in age-matched controls. During subsequent years there is a steady loss of transplanted kidneys owing to a process of chronic rejection; treatment of this is quite unsatisfactory at the moment, so many patients require a second or even a third graft over several decades, with further periods of dialysis in between.

The main problem with expanding the transplantation service is the shortage of suitable kidneys to transplant. Although the situation can be improved it is now clear that, whatever social and medical structures are present and whatever legislation is adopted, there will inevitable be a shortage of kidneys from humans. This remains the case even if kidneys from the newly dead (cadaver kidneys) are retrieved with the maximum efficiency, and living donors (usually not always from close blood relatives of the recipient) are used wherever appropriate. Hope for the future rests with solving the problems of xenotransplantation (that is using animal kidneys), probably from pigs, although baboons have also been suggested and are closer to humans. Many problems remain unsolved and it is thought highly unlikely that xenotransplantation will become a reliable treatment for end-stage renal failure within the next 10 years.

The work of a nephrologist includes the early detection and diagnosis of renal disease and the long-term management of its complications such as high blood pressure, anaemia and bone disease. The nephrologist may share the management with the general practitioner or local hospital physician, and relies on them to refer patients early for initial diagnosis and specific treatment. At any one time perhaps only 5% of patients under care are inpatients in wards, the remainder being treated in their homes, another 20% attending the renal unit regularly for haemodialysis. However, inpatient nephrology and the care of patients receiving centre-based dialysis are specialised and complex and require experienced medical advice to be available on a 24-hour basis. This implies sufficient staff to provide expert cover, cross-covering by inexperienced staff is inappropriate and to be condemned. The other 95% of renal
work is sustained on an outpatient basis; this includes renal replacement therapy by dialysis and the care of transplant patients.

E1.17 There are five major components to renal medicine.

1. Renal replacement therapy. The most significant element of work is in relation to the preparation of patients in end stage renal failure for renal replacement therapy and their medical supervision for the remainder of their lives. The patient population will present increasing challenges for renal staffing as more elderly and diabetic patients are accepted for treatment.

2. Emergency work. The emergency work associated with the speciality consists of :-

   i. Treatment of acute renal failure, often involving multiple organ failure and acute-on-chronic renal failure. Close cooperation with other medical specialties, including intensive care, is therefore a vital component of this aspect of the service.

   ii. Management of medical emergencies arising from an end stage renal failure programme. This workload is bound to expand rapidly as the number, age and co-morbidity of patients starting renal replacement therapy increase, and this may interrupt the regular care of patients already on renal replacement therapy, so increased resources may be required.

   iii. Routine nephrology. A substantial workload is associated with the immunological and metabolic nature of renal disease which requires investigative procedures in an inpatient setting. It is estimated that 10 inpatient beds per million of the population are required for this work.

   iv. Investigation and management of fluid and electrolyte disorders. This is a variable proportion of the nephrologist’s work, depending on the other expertise available in the hospital.

   v. Outpatient work. The outpatient work in renal medicine consists of the majority of general nephrology together with clinics attended by dialysis and renal transplant patients.

(Further details of renal services for renal failure, written for non-physicians, can be found in: Cameron JS. Kidney Failure – the Facts. London: Oxford University Press, 1996.)